Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05731206
Other study ID # SBB22R&40330
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date July 31, 2024
Est. completion date March 31, 2027

Study information

Verified date April 2024
Source Nutricia Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to demonstrate hypoallergenicity of a hydrolysed protein infant formula in a population of children with confirmed cow's milk allergy.


Description:

The study consists of a double-blind, placebo-controlled food challenge, followed by a single arm open challenge.


Recruitment information / eligibility

Status Suspended
Enrollment 29
Est. completion date March 31, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 0 Days to 3 Years
Eligibility Inclusion Criteria: 1. Infants and children aged up to 3 years. 2. Diagnosed with cow's milk allergy (or re-confirmed), within two months prior to the study (challenge day #1), by: 1. Physician-supervised double-blind oral food challenge; or 2. Physician-supervised open oral food challenge that elicited objective immediate allergic reactions; or 3. Report of convincing allergic reaction to cow's milk or a milk-containing food product, in conjunction with presence of milk-specific serum Immunoglobuline E (IgE) level > 0.7 kilounit per liter (U/L) or by skin prick test (wheal size = 3mm). 3. Willing to switch to a different hypoallergenic formula 4. On elimination diet (commercially available, hypoallergenic infant formula ) and free of clinical symptoms, or with controlled stable symptoms, for at least one week preceding the study (challenge day #1). 5. Expected minimal consumption of 144ml of test product/day during the open challenge. 6. Written informed consent provided by parents/guardians, according to local law. Exclusion Criteria: 1. Infants/children who are more suitable to use AAF as first-line formula, including but not limited to those with high risk of anaphylaxis (prior history of anaphylaxis and currently not using eHF) or severe forms of non-IgE-mediated CMA such as eosinophilic oesophagitis, enteropathies, or Food Protein-Induced Enterocolitis Syndrome (FPIES). 2. Diagnosis or known allergy to any of the ingredients in the test product. 3. Congenital anomalies which will interfere with oral feeding or gastrointestinal tract, other chronic diseases (including but not limited to cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, immunological and endocrine disease), major gastrointestinal disease/abnormalities, or any other medical condition that could interfere with the identification of allergic reactions. 4. (Twin / triplet) sibling of an infant/child already participating in the study. 5. Investigator's uncertainty about the willingness or ability of the subject and his/her parents to comply with the protocol requirements. 6. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study. 7. Employees and/or children/family members or relatives of employees of Nutricia Research or the participating study sites.

Study Design


Intervention

Other:
Hydrolyzed protein infant formula
Hydrolyzed protein infant formula
commercially available hypoallergenic infant formula
commercially available hypoallergenic infant formula

Locations

Country Name City State
Italy Pediatric hospital Bambino Gesù Rome

Sponsors (1)

Lead Sponsor Collaborator
Nutricia Research

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Relevant parameters routinely collected in the clinic e.g serum IgE results 25-35 days
Other Incidence, seriousness, severity and relatedness of Adverse Events Safety and tolerance parameters 25-35 days
Other Demographics characteristics Demographics characteristics at baseline
Other Relevant parameters routinely collected in the clinic e.g. skin prick test results 25-35 days
Other Birth length cm at baseline
Other Birth weight g at baseline
Other anthropometrics e.g. weight and lenght at baseline
Primary Hypoallergenicity The percentage of children tolerating the formula tested by double-blind, placebo-controlled food challenge and a subsequent open challenge. 25-35 days
See also
  Status Clinical Trial Phase
Completed NCT02738060 - The Effect of Baked Milk on Cow's Milk Allergy Phase 2
Recruiting NCT02149134 - Evaluation of the Efficacy of a New Infant Formula in Subjects With Cow's Milk Allergy Phase 2
Recruiting NCT01891916 - Effect Of Lactobacillus GG on Atopic March N/A
Completed NCT01622426 - Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy N/A
Completed NCT01634490 - Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy N/A
Completed NCT02466035 - Epigenetic Effects Involved in Children With Cow's Milk Allergy (EPICMA) N/A
Completed NCT02379598 - Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy N/A
Completed NCT04330092 - Diagnosis of Cow's Milk Protein Allergy
Not yet recruiting NCT02081651 - Parmigiano-Reggiano Cheese as a Possible Strategy to Acquire Oral Tolerance in Children With Cow's Milk Allergy Phase 3
Completed NCT03462030 - Baked Milk Oral Immunotherapy for Cow's Milk Allergy Phase 2
Completed NCT02465905 - Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : "Petit Lait" Study N/A
Not yet recruiting NCT06456541 - Infant Formula in Infants and Children With Cow's Milk Allergy N/A
Recruiting NCT02062476 - Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's Milk Allergy Phase 2
Completed NCT01589731 - Polymerized Beta-lactoglobulin Comparative Immunoreactivity N/A
Terminated NCT02405923 - Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy N/A
Terminated NCT04910373 - Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy N/A
Recruiting NCT01968278 - Use of Baked Milk in Oral Immunotherapy for Severe IgE-mediated Cow's Milk Protein Allergic Patients N/A
Withdrawn NCT01470768 - Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based (AA) Formulas N/A
Recruiting NCT05883384 - Validity of Cow's Milk-related Symptom Score Among Children Suspected to Have Cow's Milk Protein Alergy
Completed NCT01901380 - Cow's Milk Allergy and Functional Gastrointestinal Disorders N/A